000144380 001__ 144380
000144380 005__ 20240229112622.0
000144380 0247_ $$2doi$$a10.1080/10408363.2019.1633512
000144380 0247_ $$2pmid$$apmid:31314617
000144380 0247_ $$2ISSN$$a0590-8191
000144380 0247_ $$2ISSN$$a1040-8363
000144380 0247_ $$2ISSN$$a1549-781X
000144380 0247_ $$2altmetric$$aaltmetric:63717000
000144380 037__ $$aDKFZ-2019-01833
000144380 041__ $$aeng
000144380 082__ $$a570
000144380 1001_ $$aPoorebrahim, Mansour$$b0
000144380 245__ $$aProduction of CAR T-cells by GMP-grade lentiviral vectors: Latest advances and future prospects.
000144380 260__ $$aLondon$$bInforma Healthcare56466$$c2019
000144380 3367_ $$2DRIVER$$aarticle
000144380 3367_ $$2DataCite$$aOutput Types/Journal article
000144380 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1565163460_31032$$xReview Article
000144380 3367_ $$2BibTeX$$aARTICLE
000144380 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144380 3367_ $$00$$2EndNote$$aJournal Article
000144380 520__ $$aChimeric antigen receptor (CAR) T-cells represent a paradigm shift in cancer immunotherapy and a new milestone in the history of oncology. In 2017, the Food and Drug Administration approved two CD19-targeted CAR T-cell therapies (Kymriah™, Novartis, and Yescarta™, Kite Pharma/Gilead Sciences) that have remarkable efficacy in some B-cell malignancies. The CAR approach is currently being evaluated in multiple pivotal trials designed for the immunotherapy of hematological malignancies as well as solid tumors. To generate CAR T-cells ex vivo, lentiviral vectors (LVs) are particularly appealing due to their ability to stably integrate relatively large DNA inserts, and to efficiently transduce both dividing and nondividing cells. This review discusses the latest advances and challenges in the design and production of CAR T-cells, and the good manufacturing practices (GMP)-grade production process of LVs used as a gene transfer vehicle. New developments in the application of CAR T-cell therapy are also outlined with particular emphasis on next-generation allogeneic CAR T-cells.
000144380 536__ $$0G:(DE-HGF)POF3-314$$a314 - Tumor immunology (POF3-314)$$cPOF3-314$$fPOF III$$x0
000144380 588__ $$aDataset connected to CrossRef, PubMed,
000144380 7001_ $$aSadeghi, Solmaz$$b1
000144380 7001_ $$0P:(DE-HGF)0$$aFakhr, Elham$$b2
000144380 7001_ $$aAbazari, Mohammad Foad$$b3
000144380 7001_ $$aPoortahmasebi, Vahdat$$b4
000144380 7001_ $$aKheirollahi, Asma$$b5
000144380 7001_ $$aAskari, Hassan$$b6
000144380 7001_ $$aRajabzadeh, Alireza$$b7
000144380 7001_ $$aRastegarpanah, Malihe$$b8
000144380 7001_ $$aLinē, Aija$$b9
000144380 7001_ $$0P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aCid-Arregui, Angel$$b10$$eLast author$$udkfz
000144380 773__ $$0PERI:(DE-600)280641-1$$a10.1080/10408363.2019.1633512$$gp. 1 - 27$$p1 - 27$$tCritical reviews in clinical laboratory sciences$$vnn$$x1549-781X$$y2019
000144380 909CO $$ooai:inrepo02.dkfz.de:144380$$pVDB
000144380 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144380 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a30064f6b2d9ab959d35315d7668c091$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000144380 9131_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000144380 9141_ $$y2019
000144380 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144380 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144380 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144380 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCRIT REV CL LAB SCI : 2015
000144380 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144380 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144380 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000144380 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144380 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144380 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144380 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144380 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144380 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000144380 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144380 9201_ $$0I:(DE-He78)D015-20160331$$kD015$$lTranslationale Immunologie$$x0
000144380 9201_ $$0I:(DE-He78)D122-20160331$$kD122$$lAG Gezielte Tumorvakzine$$x1
000144380 980__ $$ajournal
000144380 980__ $$aVDB
000144380 980__ $$aI:(DE-He78)D015-20160331
000144380 980__ $$aI:(DE-He78)D122-20160331
000144380 980__ $$aUNRESTRICTED